Invivoscribe Technologies

Invivoscribe offers a full range of oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our cGMP facility. We are following this study testing with our internationally standardized NPM1 MRD Assay, confident that this productive partnership will bring further advancements and benefits to AML patients worldwide. Looking ahead, we are focused on further expanding and aligning our services globally. We are actively transferring and validating our service offerings of NGS tests, gene panels, bioinformatics, multiparametric flow cytometry assays, and MRD applications through our network of fully accredited laboratories in San Diego, Japan, China, and Germany to support clinical and pharma partners worldwide. Our goal is to assist our clinical trial partners seeking to expand enrollment in their international clinical trials, while maintaining patient confidentiality. Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise. Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls. Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|.